What is the current market size?

The Factor IX Concentrates Injection market size was valued at approximately USD 1.2 billion in 2023, driven by rising hemophilia B prevalence and advancements in recombinant therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2023 to 2033, fueled by increasing demand for subcutaneous delivery systems and expanding healthcare infrastructure.

What are the key growth drivers?

Key drivers include rising hemophilia B incidence, aging populations, and adoption of extended half-life Factor IX products for improved patient compliance.

What challenges does the market face?

Challenges include high treatment costs, limited reimbursement in emerging economies, and stringent regulatory requirements for novel therapies.

Which regions are market leaders?

North America leads the market due to advanced healthcare systems, followed by Europe and the Asia-Pacific region, which is growing rapidly due to improving diagnostics.

Who are the top companies?

Leading companies include Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company, and CSL Limited, dominating the market with innovative portfolios.

What future opportunities exist?

Future opportunities lie in gene therapy pipelines, expansion into emerging markets, and development of home-based treatment solutions to enhance patient care.

How is technology impacting the market?

Technological advancements in recombinant Factor IX concentrates, viral inactivation methods, and wearable injectors are enhancing efficacy and patient convenience.

What is the regulatory landscape?

Regulatory agencies like the FDA and EMA emphasize safety, purity, and potency, with evolving guidelines supporting faster approvals for bioengineered therapies.

How will the market evolve by 2030?

By 2030, the market will likely see a shift toward personalized treatments, with digital health tools and AI-driven diagnostics playing pivotal roles in patient management.

Factor IX Concentrates Injection Strategic Analysis & Growth Outlook 2033

Factor IX Concentrates Injection by Application (Hemophilia B, Acquired Coagulation Factor Deficiency), by Types (Beriplex, Profilnine, Octaplex, Prothromplex, Cofact, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Factor IX Concentrates Injection Market Size | CAGR 12% Forecast 2033

Factor IX Concentrates Injection Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $1052 million

CAGR: 12%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Factor IX Concentrates Injection Market Overview

The Factor IX Concentrates Injection market addresses hemophilia B treatment, providing therapeutic proteins to replace deficient clotting factors. This market is critical for managing bleeding disorders, with market expansion driven by rising prevalence and advanced treatment options. The Factor IX Concentrates Injection market size is projected to grow at a compound annual growth rate (CAGR) exceeding 6.5% during 2026–2033, reflecting robust industry expansion and demand for safer, longer-acting formulations. The market forecast highlights a shift toward recombinant technologies and personalized therapies, positioning this sector as a cornerstone of hematology innovation.

Loading chart…

Key forces shaping the Factor IX Concentrates Injection market include technological innovation in extended-half-life products and regulatory incentives for orphan drug development. Consumer behavior trends favor subcutaneous and on-demand therapies, reducing hospital visits. Competitive intensity is rising as biotech firms vie for market share through pipeline differentiation. North America dominates the market, accounting for 45% of global revenue in 2025, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare access and rising hemophilia awareness. Strategic collaborations and mergers are accelerating market expansion, with a focus on emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.05 billion
Revenue forecast in 2033	1.83 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Takeda; Prothya Biosolutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of hemophilia B is fueling demand for Factor IX Concentrates Injection market. As global awareness improves and diagnostic capabilities expand, more patients are being diagnosed and prescribed targeted therapies, directly increasing market size and revenue potential.

Advancements in recombinant technology are enhancing product efficacy and safety. Next-generation Factor IX concentrates with extended half-lives reduce dosing frequency, improving patient compliance and driving adoption. This innovation is a key growth forecast driver through 2030.

Restraints2 items

High treatment costs remain a significant barrier, particularly in low- and middle-income countries. The Factor IX Concentrates Injection market faces pricing pressure due to limited reimbursement frameworks and out-of-pocket expenses that deter patient access.

Stringent regulatory requirements for approval and post-market surveillance slow product commercialization. Delays in regulatory clearances across regions create bottlenecks for market expansion, especially for novel gene therapy candidates.

Opportunities2 items

Emerging markets offer untapped potential as healthcare infrastructure improves in Asia-Pacific and Latin America. Government initiatives to expand hemophilia treatment centers could boost the Factor IX Concentrates Injection market size by 15% annually in these regions.

Collaborations between biotech firms and local distributors are unlocking access to underserved populations. Tailored pricing models and patient assistance programs could further accelerate market penetration in high-growth demographics.

Challenges2 items

Supply chain vulnerabilities persist due to complex manufacturing processes and reliance on plasma-derived raw materials. Disruptions from geopolitical tensions or natural disasters risk delaying product availability.

Rising competition from biosimilars threatens pricing stability. Generic alternatives, while cost-effective, may erode market share of branded Factor IX concentrates unless innovators emphasize differentiated therapeutic benefits.

Market Segmentation

Loading chart…

The Application segment of the Factor IX Concentrates Injection market is dominated by Hemophilia B treatment, which accounts for approximately 60% of global demand due to its role in managing inherited coagulation disorders. Prophylactic use (25%) reflects growing emphasis on preventing spontaneous bleeding episodes, particularly in pediatric and adult patients. Adjunctive therapy (15%) supports surgical interventions and trauma-related hemorrhage, underscoring the product’s versatility in clinical settings. These applications collectively shape the market size by addressing unmet needs across acute and chronic care. The Factor IX Concentrates Injection segmentation by application highlights critical demand drivers and therapeutic priorities.

The Types segment is divided into Plasma-derived Factor IX and Recombinant Factor IX. Plasma-derived products (35% market share) remain cost-effective in emerging economies, though their adoption is constrained by risks of blood-borne pathogen transmission. Recombinant Factor IX (65% share) dominates due to superior safety profiles and reduced immunogenicity, aligning with regulatory and patient preference trends. This market taxonomy underscores the shift toward advanced biotechnology solutions while highlighting regional disparities in healthcare accessibility and pricing structures.

Factor IX Concentrates Injection Segmentation Breakdown10 items

Application

Hemophilia B

Acquired Coagulation Factor Deficiency

Types

Beriplex

Profilnine

Octaplex

Prothromplex

Cofact

Other

Regional Insights

Loading chart…

North America dominates the Factor IX Concentrates Injection market, accounting for ~40% share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. The region’s Factor IX Concentrates Injection market growth is further accelerated by favorable reimbursement policies and a mature hemophilia treatment ecosystem.

Europe holds ~25% of the market, supported by strong regulatory frameworks, equitable access to treatments, and a well-established hemophilia care network. Aging demographics and rising awareness of rare bleeding disorders are critical growth drivers, aligning with the Factor IX regional forecast for steady expansion.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% during 2023–2030. Key drivers include improving healthcare infrastructure, growing awareness of hemophilia therapies, and increasing local manufacturing capabilities. However, affordability challenges persist in lower-income markets.

Latin America and the Middle East & Africa collectively account for ~15% of the market. Latin America benefits from emerging partnerships with global pharma players, while the Middle East’s market is driven by government investments in rare disease programs. Both regions face hurdles in treatment accessibility due to underdeveloped healthcare ecosystems.

Competitive Landscape

The Factor IX Concentrates Injection market exhibits a moderately consolidated competitive landscape, with a mix of global leaders and regional players. Key players such as CSL Behring, Grifols, and Octapharma dominate due to their robust product portfolios and extensive regulatory approvals, while companies like Takeda and Prothya Biosolutions focus on niche markets. Competitive dynamics are driven by pricing flexibility in emerging markets, strategic partnerships to expand distribution, and continuous innovation in plasma fractionation technologies. Regulatory certifications, particularly for bioavailability and safety profiles, serve as critical differentiators. The market remains sensitive to raw material costs and compliance expenses, which influence margin strategies.

Strategies among key players emphasize M&A activity to consolidate supply chains and cross-licensing agreements to reduce R&D costs. Differentiation is achieved through proprietary purification methods and localized manufacturing to circumvent supply chain bottlenecks. However, margin pressures from payor-driven price erosion and stringent post-market surveillance requirements pose ongoing challenges. Companies are investing in digitalization of clinical trial data to accelerate approvals, while regional players leverage lower production costs in Asia-Pacific to compete against global giants.

CSL Behring: Innovation pipeline for extended half-life formulations

Grifols: Regional expansion in Latin America and Southeast Asia

Octapharma: Vertical integration to secure plasma supply

Takeda: OEM tie-ups for cost-efficient production scaling

Prothya Biosolutions: Local manufacturing to reduce import duties

CSL Behring: Premium pricing for high-purity concentrates

Key Factor IX Concentrates Injection Companies5 items

CSL Behring

Grifols

Octapharma

Takeda

Prothya Biosolutions

Market Ecosystem

The Factor IX Concentrates Injection ecosystem spans upstream raw material sourcing, midstream biopharmaceutical manufacturing, and downstream clinical delivery. Value is created through the production of hemostatic therapies for hemophilia B and acquired bleeding disorders, with control exerted across formulation innovation, regulatory compliance, and supply chain logistics.

Raw material/component suppliers — provide plasma-derived proteins, recombinant substrates, and excipients for concentrate formulation

Biopharmaceutical manufacturers — produce Factor IX concentrates via plasma fractionation or recombinant DNA technology

Technology providers — supply purification systems, lyophilization equipment, and fill/finish automation for production

Contract development and manufacturing organizations (CDMOs) — execute clinical and commercial-scale production under cGMP conditions

Distributors/logistics partners — manage cold chain storage, transportation, and inventory for temperature-sensitive injectables

Healthcare providers — administer concentrates via intravenous delivery and manage patient treatment protocols

Regulators/standards bodies — enforce drug approval pathways, post-market pharmacovigilance, and quality assurance frameworks

Control points reside in regulatory approvals, proprietary manufacturing technologies, and stable plasma supply chains. Dependency risks include raw material scarcity, evolving biosafety standards, and patent-protected formulation processes. Long-term partnerships between manufacturers and CDMOs reduce switching costs, while interoperability requirements for cold chain infrastructure shape regional distribution efficiency.

Recent Industry Insights

The Factor IX Concentrates Injection industry trends over the past 18 months reflect a dynamic landscape driven by innovation and strategic collaborations. Notably, partnerships have expanded as key players seek to strengthen their portfolios. For instance, CSL Behring partnered with a biotech firm to advance next-generation recombinant Factor IX products, while Takeda Pharmaceuticals acquired a niche developer of extended-half-life therapies, signaling confidence in long-acting solutions. Regulatory bodies have also shown flexibility, with the FDA streamlining approvals for gene therapies targeting hemophilia B, accelerating market entry for novel treatments. Meanwhile, shifts in patient preferences toward home-based self-administration have spurred demand for user-friendly injectable formats, prompting companies like Novo Nordisk to launch compact, single-dose vials. Funding activity remains robust, with startups securing over $100 million in Series B rounds to develop gene-based Factor IX therapies, underscoring investor optimism. Looking ahead, the convergence of digital health tools for treatment monitoring and advancements in subcutaneous delivery systems is expected to redefine standards of care, positioning the market for sustained growth in the coming years.

Analyst Overview

Market attractiveness remains strong due to rising hemophilia B prevalence, advancements in recombinant therapies, and favorable reimbursement policies. The Factor IX Concentrates Injection market outlook is bolstered by unmet needs in pediatric and adult patient segments, driving demand for safer, more efficient treatment options.

Competitive intensity is moderate, with established players like Bayer, Takeda, and Sobi dominating the landscape. New entrants face high R&D costs and stringent regulatory barriers, though niche opportunities exist in emerging markets and subcutaneous delivery innovations.

The long-term outlook is optimistic, supported by pipeline advancements in extended-half-life products and gene therapy candidates. However, market growth will depend on overcoming manufacturing complexities and pricing pressures from biosimilars.

Innovation landscape highlights next-generation Factor IX concentrates with reduced infrequency and improved bioavailability. Collaborations between biotech firms and contract manufacturers are accelerating R&D, though clinical translation remains challenging.

Demand–supply balance is currently stable, but rising patient access in Asia-Pacific and Latin America risks outpacing production capacity. Strategic partnerships and facility expansions are critical to addressing future demand.

Key risk factors include regulatory scrutiny over safety profiles, reimbursement restrictions in price-sensitive regions, and clinical trial uncertainties for novel therapies. Geopolitical tensions may further disrupt supply chains.

12 items

1. Executive Summary

2. Factor IX Concentrates Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Factor IX Concentrates Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Factor IX Concentrates Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Factor IX Concentrates Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Factor IX Concentrates Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Factor IX Concentrates Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Factor IX Concentrates Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Factor IX Concentrates Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Factor IX Concentrates Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Factor IX Concentrates Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Factor IX Concentrates Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Factor IX Concentrates Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Factor IX Concentrates Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Factor IX Concentrates Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Factor IX Concentrates Injection Market Competition by Key Manufacturers

9.1. Global Factor IX Concentrates Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Factor IX Concentrates Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. CSL Behring

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Grifols

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Octapharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Takeda

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Prothya Biosolutions

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Factor IX Concentrates Injection Market

Figure 4: Global Factor IX Concentrates Injection Market: Drivers

Figure 5: Global Factor IX Concentrates Injection Market: Challenges

Figure 6: Global Factor IX Concentrates Injection Market: Trends

Figure 7: Global Factor IX Concentrates Injection Market: Opportunity

Figure 8: Global Factor IX Concentrates Injection Market: Restraint

Figure 9: Global Factor IX Concentrates Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Factor IX Concentrates Injection Market Value (USD Million) By Region

Figure 19: Global Factor IX Concentrates Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Factor IX Concentrates Injection Market Value (USD Million) By Region

Figure 27: Global Factor IX Concentrates Injection Market Share (%) By: Regions (2032)

Figure 28: Global Factor IX Concentrates Injection Market Volume (K) By Region

Figure 29: Global Factor IX Concentrates Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Factor IX Concentrates Injection Market Value (USD Million) By Region

Figure 37: Global Factor IX Concentrates Injection Market Share (%) By: Regions (2032)

Figure 38: Global Factor IX Concentrates Injection Market Volume (K) By Region

Figure 39: Global Factor IX Concentrates Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Factor IX Concentrates Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Factor IX Concentrates Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Factor IX Concentrates Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Factor IX Concentrates Injection Market Value (USD Million) By Region

Table 14: Global Factor IX Concentrates Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Factor IX Concentrates Injection Market Volume (K) By Region

Table 31: Global Factor IX Concentrates Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Factor IX Concentrates Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Factor IX Concentrates Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Factor IX Concentrates Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: CSL Behring Basic Information And Sales Area

Table 52: CSL Behring. Products Portfolio

Table 53: Grifols Basic Information And Sales Area

Table 54: Grifols. Products Portfolio

Table 55: Octapharma Basic Information And Sales Area

Table 56: Octapharma. Products Portfolio

Table 57: Takeda Basic Information And Sales Area

Table 58: Takeda. Products Portfolio

Table 59: Prothya Biosolutions Basic Information And Sales Area

Table 60: Prothya Biosolutions. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Factor IX Concentrates Injection Market Value (USD Million) By Region

Table 70: Global Factor IX Concentrates Injection Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Factor IX Concentrates Injection Market Volume (K) By Region

Table 87: Global Factor IX Concentrates Injection Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Factor IX Concentrates Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.05 billion
Revenue forecast in 2033	1.83 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Takeda; Prothya Biosolutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options